Lupus Awareness Month Celebrated Community with Promise and Hope
For centuries writers have described May as a time budding with promise. How apt that it is also when...
U.S. Food and Drug Administration
Lupus Research Alliance Congratulates Dr. Robert Califf on FDA Commissioner Appointment
February 17, 2022
The Lupus Research Alliance applauds the appointment of Dr. Robert Califf as the Commissioner of the U.S....
LRA Writes President Supporting Dr. Janet Woodcock for FDA Commissioner
March 31, 2021
As part of the LRA's mission to accelerate development and availability of much-needed new diagnostics and treatments...
Over Half of People with Lupus Would Take COVID-19 Vaccine, Shows LRA Survey
Updated January 4, 2021
New York, NY– December 16, 2020. More than half of people with lupus (54%) are willing...
2021 Senate Budget Bill Includes Increases for Medical Research
November 11, 2020
The Lupus Research Alliance is pleased to share details of the 2021 spending package announced by the...
Three Healthcare Organizations Issue Statement on FDA Action to End Emergency Authorization of Medications to Treat COVID-19
June 24, 2020
Joint Statement of the American Medical Association, American Pharmacists Association, and American Society of Health-System Pharmacists on...
Aurinia Completes NDA and Requests Priority Review of Voclosoporin by FDA for Lupus Nephritis
May 28, 2020
The Lupus Research Alliance is pleased to share that Aurinia Pharmaceuticals Inc submitted a New Drug Application...
COVID-19 Caused Hydroxychloroquine Issues for Third of Lupus Patients, New LRA Survey Finds
NEW YORK, NY, May 28, 2020. More than one third of people with lupus experienced significant issues filling their...
MARCH 26 STATEMENT: Lupus Research Alliance Puts Plaquenil (Hydroxychloroquine) Shortage into Perspective for Lupus Community
March 26, 2020
The Lupus Research Alliance (LRA), the world’s leading research organization dedicated to lupus research, continues to watch...